Had a look at August 2022 peak at $2.18 SP = $1,447.37M MC (had 26.3M less shares) / $41.9M FY22 revenue = x34.5.
At $4.01 SP peak in December 2020 = $2,662.37M MC / $19.1M FY20 revenue = x139.4. US $15M BARDA funding, Taiwan FDA approval, distributors for Greece, Finland, Belgium, Netherlands, Sweden & US FDA trial approval along with Covid pump resulted in MC becoming very frothy.
By May 2022 at SP lows the x139.4 was trimmed to x15.5. Mean reverted to x34.5 by August 2022 & now down to around x15 again.
Another of many stocks that has been overstretched in both directions.
PNV - Chart, page-16784
-
- There are more pages in this discussion • 3,045 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.53 |
Change
0.100(4.12%) |
Mkt cap ! $1.747B | |||
| Open | High | Low | Value | Volume |
| $2.44 | $2.54 | $2.41 | $2.280M | 916.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3111 | $2.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.54 | 7804 | 2 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |